Royal Bank of Canada’s CASI Pharmaceuticals CASI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,950
| Closed | -$8K | – | 7162 |
|
|
2025
Q4 | $8K | Hold |
9,950
| – | – | ﹤0.01% | 6513 |
|
|
2025
Q3 | $16K | Hold |
9,950
| – | – | ﹤0.01% | 6299 |
|
|
2025
Q2 | $11K | Buy |
9,950
+250
| +3% | +$458 | ﹤0.01% | 6443 |
|
|
2025
Q1 | $21K | Buy |
9,700
+2,800
| +41% | +$6.85K | ﹤0.01% | 5895 |
|
|
2024
Q4 | $20K | Hold |
6,900
| – | – | ﹤0.01% | 6104 |
|
|
2024
Q3 | $43K | Hold |
6,900
| – | – | ﹤0.01% | 5770 |
|
|
2024
Q2 | $38K | Buy |
+6,900
| New | +$21.4K | ﹤0.01% | 5775 |
|
|
2023
Q4 | – | Sell |
-18
| Closed | – | – | 7146 |
|
|
2023
Q3 | $0 | Hold |
18
| – | – | ﹤0.01% | 7110 |
|
|
2023
Q2 | $0 | Hold |
18
| – | – | ﹤0.01% | 7279 |
|
|
2023
Q1 | $0 | Sell |
18
-40
| -69% | -$77 | ﹤0.01% | 7092 |
|
|
2022
Q4 | $0 | Buy |
58
+40
| +222% | +$79 | ﹤0.01% | 7255 |
|
|
2022
Q3 | $0 | Hold |
18
| – | – | ﹤0.01% | 7468 |
|
|
2022
Q2 | $0 | Hold |
18
| – | – | ﹤0.01% | 7390 |
|
|
2022
Q1 | $0 | Hold |
18
| – | – | ﹤0.01% | 7756 |
|
|
2021
Q4 | $0 | Hold |
18
| – | – | ﹤0.01% | 7660 |
|
|
2021
Q3 | $0 | Sell |
18
-431
| -96% | -$5.83K | ﹤0.01% | 7641 |
|
|
2021
Q2 | $7K | Sell |
449
-169
| -27% | -$2.84K | ﹤0.01% | 6969 |
|
|
2021
Q1 | $14K | Buy |
618
+102
| +20% | +$2.86K | ﹤0.01% | 6630 |
|
|
2020
Q4 | $15K | Buy |
516
+501
| +3,340% | +$10.9K | ﹤0.01% | 6189 |
|
|
2020
Q3 | $0 | Sell |
15
-1,747
| -99% | -$32.9K | ﹤0.01% | 6638 |
|
|
2020
Q2 | $44K | Sell |
1,762
-2,027
| -53% | -$44K | ﹤0.01% | 5276 |
|
|
2020
Q1 | $77K | Buy |
3,789
+1,708
| +82% | +$40.7K | ﹤0.01% | 4926 |
|
|
2019
Q4 | $64K | Buy |
2,081
+317
| +18% | +$10.3K | ﹤0.01% | 5323 |
|
|
2019
Q3 | $59K | Buy |
1,764
+9
| +0.5% | +$289 | ﹤0.01% | 5052 |
|
|
2019
Q2 | $56K | Sell |
1,755
-9
| -0.5% | -$287 | ﹤0.01% | 5212 |
|
|
2019
Q1 | $50K | Sell |
1,764
-43
| -2% | -$1.5K | ﹤0.01% | 5154 |
|
|
2018
Q4 | $73K | Sell |
1,807
-102
| -5% | -$3.86K | ﹤0.01% | 4894 |
|
|
2018
Q3 | $89K | Buy |
1,909
+153
| +9% | +$10.7K | ﹤0.01% | 4923 |
|
|
2018
Q2 | $144K | Buy |
1,756
+1
| +0.1% | +$67 | ﹤0.01% | 4607 |
|
|
2018
Q1 | $74K | Sell |
1,755
-10
| -0.6% | -$373 | ﹤0.01% | 4852 |
|
|
2017
Q4 | $58K | Buy |
1,765
+8
| +0.5% | +$217 | ﹤0.01% | 5101 |
|
|
2017
Q3 | $31K | Buy |
1,757
+2
| +0.1% | +$23 | ﹤0.01% | 5704 |
|
|
2017
Q2 | $18K | Sell |
1,755
-2
| -0.1% | -$21 | ﹤0.01% | 5579 |
|
|
2017
Q1 | $25K | Sell |
1,757
-202
| -10% | -$2.75K | ﹤0.01% | 5508 |
|
|
2016
Q4 | $22K | Buy |
1,959
+2
| +0.1% | +$27 | ﹤0.01% | 5714 |
|
|
2016
Q3 | $21K | Buy |
1,957
+3
| +0.2% | +$33 | ﹤0.01% | 5540 |
|
|
2016
Q2 | $22K | Buy |
1,954
+199
| +11% | +$2.51K | ﹤0.01% | 5463 |
|
|
2016
Q1 | $18K | Buy |
1,755
+1
| +0.1% | +$10 | ﹤0.01% | 5523 |
|
|
2015
Q4 | $17K | Buy |
1,754
+1,739
| +11,593% | +$19.7K | ﹤0.01% | 5776 |
|
|
2015
Q3 | $0 | Hold |
15
| – | – | ﹤0.01% | 6640 |
|
|
2015
Q2 | $0 | Hold |
15
| – | – | ﹤0.01% | 6584 |
|
|
2015
Q1 | $0 | Hold |
15
| – | – | ﹤0.01% | 6141 |
|
|
2014
Q4 | $0 | Hold |
15
| – | – | ﹤0.01% | 6171 |
|
|
2014
Q3 | $0 | Buy |
+15
| New | +$267 | ﹤0.01% | 5972 |
|
|
2014
Q2 | – | Sell |
-15
| Closed | – | – | 5940 |
|
|
2014
Q1 | $0 | Hold |
15
| – | – | ﹤0.01% | 5908 |
|
|
2013
Q4 | $0 | Sell |
15
-1
| -6% | -$17 | ﹤0.01% | 5932 |
|
|
2013
Q3 | $0 | Hold |
16
| – | – | ﹤0.01% | 6088 |
|
|
2013
Q2 | $0 | Buy |
+16
| New | +$310 | ﹤0.01% | 5821 |
|
Other funds holding CASI
Royal Bank of Canada's CASI Position: Q1 2026 in Review
Royal Bank of Canada sold out of CASI Pharmaceuticals (CASI) in Q1 2026, closing a stake of 9,950 shares — an estimated $8K sold.
Royal Bank of Canada first reported a position in CASI in Q2 2013 and held it in 48 quarters. The position peaked at $144K in Q2 2018. 1 fund tracked by Wall St. Rank holds CASI as of Q1 2026.
- Royal Bank of Canada reported no remaining CASI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Royal Bank of Canada sold 9,950 CASI Pharmaceuticals shares in Q1 2026, an estimated $8K.
- Royal Bank of Canada first reported a position in CASI Pharmaceuticals in Q2 2013 and held it in 48 quarters.
- Royal Bank of Canada's CASI Pharmaceuticals position peaked at $144K in Q2 2018.
- 1 fund tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.